Relief for Amylyx as FDA clears controversial ALS drug Relyvrio
pharmaphorum
SEPTEMBER 30, 2022
Faced with the backlash, the FDA took the highly unusual step of convening another advisory committee meeting earlier this month and, amid emotional pleas from patients and doctors, this time the vote went the other way by a seven-to-two margin. — The ALS Association (@alsassociation) September 29, 2022. The organisation contributed $2.2
Let's personalize your content